Cover Image

Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the Near trial

BACKGROUND: The aim of this study was to evaluate efficacy and toxicity of radioimmunotherapy with intensity-modulated radiation (IMRT) and cetuximab in stage III nonsmall cell lung cancer (NSCLC). METHODS: NEAR was a prospective, monocentric phase II trial including patients unfit for chemoradiatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Jensen, Alexandra (Author) , Münter, Marc (Author) , Bischoff, Helge (Author) , Haselmann, Renate (Author) , Haberkorn, Uwe (Author) , Huber, Peter E. (Author) , Thomas, Michael (Author) , Debus, Jürgen (Author) , Herfarth, Klaus (Author)
Format: Article (Journal)
Language:English
Published: 24 January 2011
In: Cancer
Year: 2011, Volume: 117, Issue: 13, Pages: 2986-2994
ISSN:1097-0142
DOI:10.1002/cncr.25888
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.25888
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.25888
Get full text
Author Notes:Alexandra D. Jensen, Marc W. Münter, Helge G. Bischoff, Renate Haselmann, Uwe Haberkorn, Peter E. Huber, Michael Thomas, Jürgen Debus, and Klaus K. Herfarth
Description
Summary:BACKGROUND: The aim of this study was to evaluate efficacy and toxicity of radioimmunotherapy with intensity-modulated radiation (IMRT) and cetuximab in stage III nonsmall cell lung cancer (NSCLC). METHODS: NEAR was a prospective, monocentric phase II trial including patients unfit for chemoradiation regimen; treatment consisted of IMRT and weekly cetuximab followed by a 13-week maintenance period. Primary endpoints were toxicity and feasibility; secondary endpoints were remission rates at completion of the planned treatment according to Response Evaluation Criteria In Solid Tumor (RECIST), local/distant progression-free survival, and overall survival. RESULTS: Thirty patients (median age, 71 years) were treated within the protocol. Overall response rate was 63% (partial remission: 19 of 30) patients. Median locoregional, distant, overall progression-free survival was 20.5, 10.9, and 8.5 months. Median overall survival was 19.5 months, with an estimated 1- and 2-year survival of 66.7% and 34.9% respectively. Stage (IIIA vs IIIB) and histologic subtype did not have a significant impact on survival rates in our patients. Treatment was tolerated well with only mild toxicity (°3 pneumonitis: 3.3%, any °3 acute toxicity: 36.7%). CONCLUSIONS: Combined radioimmunotherapy with cetuximab was safe and feasible, especially in elderly patients with multiple comorbidities. A more intensified regimen warranted investigation.
Item Description:Gesehen am 05.07.2022
Physical Description:Online Resource
ISSN:1097-0142
DOI:10.1002/cncr.25888

Similar Items